Kornimate/medical-research-clean huggingface dataset:
pain management during a photodynamic therapy session on the vertex for actinic keratosis: tumescent anesthesia interest

Conditions: Pain; Actinic Keratosis; Analgesia; Phototerapy; Vertex

Summary: this study focus on the efficacity of tumescent anesthesia in pain management during a photodynamic therapy on the vertex for treatment of actinic keratosis. to do this we carried out a prospective, randomized, controlled, open-ended study. our aim is to show a 40% reduction in pain during photodynamic therapy session compared to a conventionally used analgesic method (paracetamol + cold water)


Eligibility criteria:
inclusion criteria: * patients over the age of 18 * diagnosis of clinical or histological actintic keratoses validated by a dermatologist * more than 4 vertex actinic keratoses lesions that can be treated with a dynamic phototherapy session * free subject, without guardianship or curatorship or subordination * person affiliated or beneficiary of a social security plan * informed and signed consent by the patient after clear and fair information about the study exclusion criteria: * known lidocaine hydrochlostate hypersensitivity, local amide-binding anesthetics or one of the excipients * hypersensitivity to paracetamol or one of the excipients * weight \< 50 kg * patients with an elongated tq interval at the ecg (\>450 ms in men and \>470 ms in women) * patients with recurrent porphyria * severe hepato-cellular insufficient patients * patients who have received treatment for actinic keratoses in the last three months (cryotherapy, 5-fluorouracil, imiquinod, daylight-ptd) * patients who have already participated in this study * people who do not have a social security plan or do not benefit from it through a third party. * persons with enhanced protection, namely minors, persons deprived of their liberty by judicial or administrative decision, persons staying in a health or social institution, adults under legal protection and finally the sick in an emergency situation. * pregnant or lactating women, women of childbearing age who do not have effective contraception (hormonal/mechanical: per bone, injectable, transcutaneous, implantable, intrauterine device, or surgical: tubal ligation, hysterectomy, total oophorectomy). * concurrent participation in another clinical research study.
comparision of the use in marcaine and chloroprocaine in rachianesthesia for the surgical correction of inguinal hernia.

Conditions: Pain

Summary: comparison the use of marcaine and chloroprocaine in rachianesthesia for a surgical correction of inguinal hernia. comparision between acute and chronic (3 months and 6 months) pain.


Eligibility criteria:
inclusion criteria: * adults under rachianesthesia exclusion criteria: * personal history of gastric ulcus * asa 4 * emergency * combined surgery

Keywords: all
a clinical trial to compare pharmacokinetics of two different peg-rhgh preparations

Conditions: Pediatric Growth Hormone Deficiency (PGHD)

Summary: the purpose of this study is to compare the pharmacokinetics of the two different peg-rhgh preparations after a single administration.


Eligibility criteria:
inclusion criteria: * healthy male aged ≥18 years old and≤45 years old; * the body mass index (bmi): 19-26 kg/m2 (inclusive), and body weight ≥50 kg; * normal results of physical examination, vital signs, laboratory tests, 12 lead-ecg, chest x-ray, abdominal ultrasound, or non-clinical significance changes in the assessments above. exclusion criteria: * subjects with a history of hypersensitivity reactions or clinically significant hypersensitivity reactions to drugs containing; * subjects with a clear history of disorders of the central nervous system, cardiovascular system, digestive system, respiratory system, urinary system, blood system, metabolic system, etc., or other diseases deemed unsuitable for participation in the trials by the investigators; * subjects with severe infection, severe trauma, or major surgery prior to screening; * subjects who have received blood transfusions, had blood donors, or lost blood before screening; * subjects who have positive results of human immunodeficiency virus antibodies (hiv-ab), or hepatitis b surface antigen (hbsag), or hepatitis c virus antibodies (hcv-ab), or syphilis specific antibodies (tppa); * subjects who have participated in clinical trials for medication or medical device prior to screening;etc.
chart review of treatments received by patients diagnosed with soft tissue sarcoma

Conditions: Sarcoma

Summary: to review the outcome of patients with soft tissue sarcoma treated with chemotherapy from 2004 and 2005.

chart review of patients with soft tissue sarcoma treated with chemotherapy from 2004 and 2005 to determine outcome

Eligibility criteria:
inclusion criteria: * patients diagnosed with soft tissue sarcoma treated with chemotherapy form 2004 and 2005. exclusion criteria: * not specified
eicosapentaenoic acid (epa) for treatment of colorectal cancer liver metastases

Conditions: Colorectal Cancer

Summary: eicosapentaenoic acid (epa) is a naturally occuring omega-3 polyunsaturated fatty acid found in oily fish. epa has anti-colorectal (bowel) cancer activity in experimental models. this trial will test whether epa reduces markers of tumour growth, and is safe and well tolerated,in patients with colorectal cancer liver metastases awaiting surgery.

a double-blind, randomised, placebo-controlled trial of eicosapentaenoic acid (epa), in the free fatty acid form, 2g daily in patients who will undergo liver resection surgery for colorectal cancer liver metastases.

Eligibility criteria:
inclusion criteria: * age greater than or equal to 18 years * either sex * liver resection deemed clinically appropriate for management of metastatic colorectal cancer * duration between decision to perform liver resection and surgery greater than 2 weeks * ability to give written informed consent and follow study protocol * telephone contact possible exclusion criteria: * neo-adjuvant chemotherapy for colorectal cancer (crc) liver metastasis * chemotherapy for any cancer in the previous 3 months * known bleeding diathesis or anticoagulation therapy * fish or seafood allergy * use of fish oil supplements (eg. cod liver oil) and unwilling to stop for the duration of the study * pregnancy * non-aspirin non-steroidal anti-inflammatory (nsaid) or corticosteroid use * renal impairment (serum creatinine \>150) * active inflammatory disease (e.g. inflammatory bowel disease, rheumatoid arthritis).

Keywords: colorectal neoplasms fish oils fatty acids, omega-3 eicosapentaenoic acid liver metastases randomised controlled trial
the effect of the mobile eeg-neurofeedback in healthy child and adolescent

Conditions: Internet Addiction

Summary: the objective of this study was to ascertain the therapeutic impact of mobile neurofeedback (mnf) in neurotypical children when compared to sham mnf. clinical assessments were conducted both before and after the mnf intervention, and the effectiveness of the intervention was to be validated through these evaluations.

neurotypical children aged 10-15 participated in the study. all subjects were assessed using the kiddie schedule for affective disorders and schizophrenia present and lifetime version korean version (k-sads-pl-k) and confirmed to have no psychiatric symptoms. the participants were randomly assigned to the mnf active (n=31) or sham control (n=30) groups. the mnf program was administered using a mobile app (equipped with a headset with a 2-channel eeg sensor) for 30 min/day, 3 days/week, for 3 months. all participants and their parents completed self-report scales and participants complete neurocognitive function assessments including the continuous performance test, stroop, children's color trails test-1 and 2, and intelligence test at baseline and after the 3-month mnf program.

Eligibility criteria:
inclusion criteria: child participants ranging from 8 to 15 years of age, who were recruited from the department of psychiatry at daegu catholic university medical center between 2019 and 2021 exclusion criteria: history of congenital genetic diseases history of brain damage history of neurological disorders history of psychiatric conditions such as schizophrenia spectrum disorder, autism spectrum disorder, obsessive-compulsive disorder, major depressive disorder, or bipolar disorder participants with an iq below 70, as determined by the korean-wechsler intelligence scale for children-fourth edition (k-wisc-iv)

Keywords: mobile neurofeedback neurotypical internet addiction
milk protein feeding after aerobic exercise in older adults with pre-diabetes taking the biguanide metformin

Conditions: Physical Activity

Summary: the investigators propose that post-exercise milk protein feeding will enhance the mitochondrial protein synthesis (biogenesis) response to an exercise-training program. in addition, the investigators propose that this stimulatory effect of protein feeding will overcome the potential blunting effect of metformin on exercise responses. the investigators will investigate these outcomes over a 12-week exercise-training program in older adults with pre-diabetes with or without metformin treatment.

this is a randomized, placebo controlled, double blind study. 60 men and women over the age of 55 with indications of pre-diabetes will be recruited for participation and randomly assigned to one of four 12 week exercise training programs: 1)supervised aerobic exercise 3 days per week followed by a carbohydrate drink along with daily oral administration of metformin. 2) supervised aerobic exercise 3 days per week followed by a protein drink along with daily oral administration of metformin. 3) supervised aerobic exercise 3 days per week followed by a carbohydrate drink along with daily oral administration of matching placebo. 4) supervised aerobic exercise 3 days per week followed by a protein drink along with daily oral administration of placebo. daily administration of metformin will begin as one 500 mg tablet for the first week and will increase by 500 mg/day/week until reaching 2000 mg/day by week 4 during a 12 week exercise training program. the titration dosing scheme and taking metformin/placebo with meals will help reduce the most common side effects (i.e.,gastrointestinal discomfort). if participants experience gastrointestinal discomfort, the dose will be lowered to 1500 mg/day.

Eligibility criteria:
inclusion criteria: * 55 years or older * individuals with prediabetes defined as impaired fasting glucose (100 to 126 mg/dl), hba1c (5.7-6.4%), and/or impaired glucose tolerance defined as 2 hour postprandial blood glucose of 140 to 200 mg/dl. exclusion criteria: * medications contraindicated with metformin (dofetilide, lamotrigine, pegvisomant, somatropin, trimethoprim, trospium, gatifloxacin, cephalexin, cimetidine, dalfampridine) * recent (less than 6 weeks) or planned imaging that requires iv contrast, * renal dysfunction creatinine ≥ 1.3 mg/dl in men or ≥ 1.2 mg/dl in women * alanine aminotransferase (alt) levels exceed 52 iu/l * heart, kidney or liver disease * type i or type ii diabetes * anti-coagulant therapy (warfarin/heparin) * lung/respiratory dysfunction * medications affecting primary outcomes * lactose intolerant * tobacco use * heavy alcohol use * cancer * lidocaine allergy
impact on elderly skin due to wet pad application.

Conditions: Incontinence

Summary: the clinical study aims to measure the changes in the stratum corneum on older healthy participants due to the application of a wet pad on the forearm. participants are subject to baseline measures of transepidermalwaterloss (tewl), skin hydration (sh), ph and water profile (raman spectroscopy). dry or wet pads are then added to the skin and worn for two hours. after a recovery period, the skinsurfacewaterloss (sswl) and skin hydration and water profile is measured. the study is conducted over a single visit. pads on the arms consist of incontinence product cutouts and are loaded to 50% or 100% capacity. the endpoints are the changes in stratum corneum as measured by the instruments during the visit.


Eligibility criteria:
inclusion criteria: 1. men and women ≥ 65 years. 2. mentally and physically able to participate in this study. 3. written informed consent to participate in this study. 4. intact skin on the volar forearms without skin irritation. exclusion criteria: 1. have any known allergies or intolerances to one or several components of the absorbing incontinence product. 2. suffer from excessive sweating, hyperhidrosis. 3. have any other condition that makes participation in the clinical investigation inappropriate, as judged by investigator. 4. not be of childbearing potential. 5. have an alcohol and/or drug dependency.
drug screening of pancreatic cancer organoids developed from eus-fna guided biopsy tissues

Conditions: Pancreatic Cancer; Pancreas Adenocarcinoma

Summary: we are going to establish "organoid" models from pancreatic cancer biopsies achieved via eus-fna. then the sensitivity of the selected fda-approved anti-cancer drugs will be tested in these organoids.

the survival rate of pancreatic cancer, a kind of malignant tumor, remains poor due to lack of effective treatments. recently, a new model called "organoid" has been generated from human and murine pancreatic cancer tissues. these organoids are developed from large pieces of surgical tissues or small biopsies taken from eus-fna guided samples. here in our study we are going to establish "organoid" models from pancreatic cancer biopsies achieved via eus-fna. after successful generation of these organoids, we will treat them with the selected fda-approved anti-cancer drugs, and assess the responses to these anti-cancer agents in our established organoids.

Eligibility criteria:
inclusion criteria: * 1) patients suspected to have pancreatic cancer who will receive eus-fna for diagnosis; 2) patients who have signed the informed consent. exclusion criteria: * 1) those who are under the age of 18; 2) patients who have received adjuvant chemoradiotherapies or other anti-tumor therapies; 3) patients with critical illness and cannot tolerate the operations; 4) women who have been pregnant or are planning to be pregnant.

Keywords: pancreatic cancer eus-fna organoid
besifloxacin ophthalmic suspension verses gatifloxacin ophthalmic solution in neonates with bacterial conjunctivitis

Conditions: Bacterial Conjunctivitis

Summary: the objective of this study is to evaluate the safety and efficacy of besivance (besifloxacin 0.6%) ophthalmic suspension compared to gatifloxacin 0.3% ophthalmic solution when administered three times daily (tid) for seven days to neonatal subjects who are 31 days or younger on the day of randomization (visit 1).


Eligibility criteria:
inclusion criteria: * subjects who have a clinical diagnosis of acute bacterial conjunctivitis and exhibit conjunctival discharge and redness in at least one eye. a minimum score of 1 should be present for discharge and a minimum score of 1 for conjunctival hyperemia in the same eye. exclusion criteria: * subjects with conjunctivitis signs and/or symptoms suggestive of fungal, protozoal, or viral etiology in either eye. * subjects who require or are expected to require (other than study medication) use of any topical ocular medication in either eye, or systemic medications during the course of the study or prior to day 1 specified in the protocol as ineligible. * subjects with any abnormality of the ocular anatomy or ocular disease/disorder specified in the protocol as ineligible. * subjects with systemic disease/disorder specified in the protocol as ineligible. * subjects who have a known or suspected poor tolerance, sensitivity, or allergy to the study medications or any of their components. * subjects who have a condition or are in a situation which in the investigator's opinion may impact their safety or would negatively affect the conduct or outcome of the study.

Keywords: ocular infections, bacterial
comparison of two different intensity exercises on young women with obesity

Conditions: Obesity; Exercise Training

Summary: obesity is one of the most common preventable public health problems. diet regulation and exercise practices are the most commonly used methods in reducing fat tissue. there are various exercise methods applied in the weight loss process and the effects of different types of exercise modalities on body fat rate and metabolic status.the aim of our study is to determine the effects of high intensity interval exercise and moderate intensity continuous exercise on serum , omentin, leptin and adiponectin levels, anthropometric measurements used in obesity follow up, body fat percentage and their effects on the quality of sleep and life of women with obesity.

female participants aged 18-45 with a body mass index of 30-40 kg/m² who met the inclusion and exclusion criteria were randomized into two groups using a simple randomization method using a computer. one group will perform high intensity interval exercise with an ergoline bicycle ergometry device for 45 minutes a day, 5 days a week for 8 weeks, while the other group will perform moderate intensity continuous exercise on the same device. peripheral venous blood samples will be taken from all participants at the beginning and end of the study, anthropometric measurements used in obesity monitoring of all participants will be taken and noted, and participants will be asked to fill out questionnaires containing questions about their sleep and quality of life. the analysis of the blood samples taken will be carried out in the biochemistry laboratory of kırşehir ahi evran university. the data of our study will be analyzed with the statistical package program spss version 23.0.

Eligibility criteria:
inclusion criteria: * female between the age of 18-45 * bmi 30-40 kg/m² * primary obesity exclusion criteria: * patients with cardiac, pulmonary, endocrinological, rheumatological diseases * pregnancy and breastfeeding * using antipsychotics, antidepressants (lithium, tricyclic antidepressants, mono amino oxidase inhibitors), anticonvulsants, antihistamines, glucocorticoids, antidiabetics (sulfonylureas, insulins, glitazones) sex hormones * using oral contraceptives * history of bariatric surgery * patients using obesity medication in the last 6 months, complying with a regular diet and exercise program * presence of orthopedic or neurological problems that difficulty of participate aerobic exercise training

Keywords: obesity exercise training adipokines
sleeper stretch in crossfit participants

Conditions: Shoulder Pain

Summary: the purpose of this study is to compare the efficacy of the sleeper stretch in improving shoulder range of motion, strength and upper body performance in crossfit athletes.


Eligibility criteria:
inclusion criteria: • regularly active (attending crossfit \> 2x per week) exclusion criteria: * positive test for labral lesions or rotator cuff tears * history of recent fracture * orthopedic surgery in the upper limbs or cervical region * any other current injury that would prevent participation in regular work-shift activities

Keywords: crossfit sleeper stretch
use of an intra uterine balloon to prevent recurrent adhesions (repair)

Conditions: Adhesion; Uterus, Internal

Summary: patients suffering of subfertility as a consequence of intrauterine adhesions could be treated with hysteroscopic adhesiolysis. adhesion recurrence may occur postoperative. an intrauterine balloon, inserted after hysteroscopic adhesiolysis, may prevent adhesion reformation. a foley catheter can serve for this purpose, but its not ideal. cook medical® developed a hearth shaped intrauterine balloon to reduce bleeding after intrauterine surgery. we aimed to perform a pilot study of 10 procedures with insertion of a hearth shaped intrauterine balloon as antiadhesion method subsequent to a hysteroscopic adhesiolysis, to study its feasibility in terms of surgeon's and patient's experience.


Eligibility criteria:
inclusion criteria: * patients with intra uterine adhesions scheduled for hysteroscopic adhesiolysis

Keywords: antiadhesion treatment asherman's syndrome hysteroscopic adhesiolysis intrauterine adhesions intrauterine balloon
per-oral endoscopic myotomy (poem) in patients with postfundplication dysphagia

Conditions: Dysphagia; Dysphagia, Esophageal; Healthy

Summary: laparoscopic fundoplication represents the standard antireflux procedure, when conservative measures fail. however, any type of fundoplication may be accompanied by adverse events. postfundoplication dysphagia (pfd) may hamper results of anti-reflux surgery. endoscopic pneumatic dilation has been considered as the first line treatment option for persistent pfd. however, studies have not confirmed its effectiveness in this indication. peroral endoscopic myotomy (poem) became a standard treatment for the management of esophageal achalasia and moreover has also been assessed in a small cohort of patients with refractory pfd and some patients achieved significant treatment success. we plan to perform a prospective international cohort multicenter study assessing the efficacy of poem in patients with persistent and severe pfd.


Eligibility criteria:
inclusion criteria: 1. patients after laparoscopic fundoplication procedure by nissen (total, 360°), dor (anterior, 180°) or toupet (posterior, 270°) for gastroesophageal reflux disease no later than 10 years before enrolment. 2. refractory (\> 6 months) and severe dysphagia after fundoplication procedure defined as an eckardt score ≥3 and mellow - pinkas score ≥2 at baseline. 3. x-ray (contrasted radiographic examination of the esophagus) characterized by both: a.) tapered narrowing of the distal esophagus and gej; b.) partial/total stagnation of the contrast solution above the gej 4. endoluminal planimetry: egj-di \< 3 mm2/mmhg (with 40ml) 5. age above 18 years 6. signed informed consent form exclusion criteria: 1. no previous attempt with at least one prokinetic drug 2. previous esophageal myotomy (open, laparoscopic or endoscopic) 3. primary esophageal motility disorder (achalasia etc.) 4. active erosive esophagitis 5. active peptic ulcer disease 6. esophageal stricture (peptic, malignant, other) 7. partial or complete supradiaphragmatic migration of the wrap and/or stomach (hinder type iii - iv), large hiatal hernia more than 5 cm 8. known eosinophilic esophagitis 9. severe coagulopathy 10. esophageal or gastric varices 11. advanced liver cirrhosis (child b or child c) 12. pregnancy or puerperium 13. malignant or pre-malignant esophageal diseases (dysplasia): patients with a history of such disease after its cure are eligible for enrolment 14. any other condition, which in the opinion of the investigator would interfere with study requirements 15. known gastroparesis